The Principal Investigator (PI) is the responsible investigator at a clinical trial site who leads and supervises a clinical trial in accordance with the approved clinical trial protocol, the principles of Good Clinical Practice (GCP), and applicable regulatory requirements. The responsibilities of the PI are clearly defined in the ICH E6(R3) guideline as well as in EU Regulation No. 536/2014 (CTR).
Tasks and responsibilities
The Principal Investigator bears overall responsibility for the conduct of the clinical trial at the trial site. Key tasks include ensuring the informed consent of all trial participants, delegating tasks to qualified personnel with appropriate documentation in the delegation log, and providing medical care to study participants. The PI is responsible for the complete and correct collection and documentation of all study-relevant data in the Case Report Form (CRF), as well as for the immediate reporting of serious adverse events (SAEs) to the sponsor.
Furthermore, the PI ensures the availability of sufficient personnel and infrastructural resources at the trial site, grants the sponsor, monitors, and authorities access to study-relevant documents, and cooperates during Source Data Verification (SDV) as well as during audits and inspections. The proper archiving of all trial site documents in the Investigator Site File (ISF) also falls within their area of responsibility.
Qualification Requirements
The PI must have sufficient training, experience, and knowledge of GCP principles. Generally, a medical license is required; however, in certain non-interventional or device studies, other healthcare professionals may also serve as the PI. A current GCP training certificate and evidence of relevant clinical experience are reviewed by the sponsor during the feasibility process and site selection. The sponsor documents the qualification in the investigator selection and in the Investigator Curriculum Vitae (CV).
PI vs. Sub-Investigator
When delegating tasks to sub-investigators, the overall responsibility remains with the PI. Sub-investigators are listed by name in the delegation log and may only perform tasks explicitly assigned to them by the PI. The clinical monitor verifies the completeness of the delegation log during each monitoring visit. In multicenter studies, a Coordinating Investigator is often appointed to coordinate activities between the trial sites without diminishing the responsibility of the individual PIs.
The qualification of the PI is also of particular importance during inspections by authorities such as the BfArM, EMA, or FDA. Inspectors review the delegation log, GCP training history, and the availability of the PI for study-relevant decisions. Incomplete evidence of qualification or a deficient delegation log are among the most common findings in PI-related GCP inspections and can, in the worst case, lead to the unusability of the entire study data and the rejection of marketing authorization applications.
Significance for Sponsor and CRO
The selection of qualified and experienced Principal Investigators is a critical success factor for the timely and quality-assured conduct of clinical trials. Contract Research Organizations (CROs) support sponsors in identifying suitable investigators, conducting feasibility assessments, and training the trial sites. Good cooperation between the sponsor, CRO, and PI is crucial for compliance with the protocol, data quality, and patient safety.
From the CRO’s perspective, the quality of cooperation with the Principal Investigator is a key factor for study success. Experienced Clinical Operations teams conduct structured Site Qualification Visits, during which not only the infrastructure but also the experience and motivation of the PI are evaluated. Recruitment potential, GCP compliance history, and the quality of previous monitoring visits are factored into site selection. During the conduct of the study, the PI is the primary point of contact for the Clinical Monitor and the Clinical Research Associate (CRA). Regular Investigator Meetings promote exchange between trial sites and strengthen the shared understanding of the protocol. Transparent communication between the PI, sponsor, and CRO is essential to identify and counteract protocol deviations at an early stage.
Frequently Asked Questions
What distinguishes the Principal Investigator from the Sponsor?
The sponsor is the person or organization that takes responsibility for the initiation, management, and financing of a clinical trial. The PI is responsible for the operational conduct at the trial site. The sponsor and PI work together based on a clinical trial agreement that regulates mutual obligations. In Investigator-Initiated Trials (IITs), the PI may simultaneously act as the sponsor.
What are the PI’s GCP obligations regarding SAE reporting?
The PI is obliged to report serious adverse events (SAEs) immediately—usually within 24 hours of becoming aware of them—to the sponsor. The sponsor forwards the report as a SUSAR to the competent authorities and the ethics committee where applicable. The PI documents all SAEs completely in the CRF and provides the sponsor with all medical information necessary for the causality assessment.
Can a PI work on several studies simultaneously?
Yes, a PI can work as an investigator on several clinical trials at the same time. However, the sponsor is obliged to ensure, as part of the feasibility assessment, that the PI has sufficient time resources and capacity to properly supervise all studies. Overburdening the PI is considered a risk factor for protocol deviations and data quality issues and is critically evaluated during monitoring visits and inspections.
Regulatory References
- ICH E6(R3): Good Clinical Practice – Section 4: Investigator
- EU Regulation No. 536/2014 (CTR), Articles 49–52: Investigator Obligations
- AMG §40–42a: Requirements for clinical trials in Germany
- EMA GCP Inspections: Common findings relating to Investigator responsibilities